Clearmind Medicine Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of June 2026 for Clearmind Medicine Inc., a foreign private issuer. The filing details a specific financing transaction executed on June 1, 2026, under an existing securities purchase agreement framework.
Key Financial Metrics
- Debt Issuance: The Company agreed to issue convertible promissory notes with an aggregate principal amount of $1,500,000.
- Cash Proceeds: The aggregate purchase price payable in cash is $1,350,000, representing 90% of the principal amount.
- Liquidity Impact: The transaction is expected to close on or about June 1, 2026, providing immediate liquidity.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, or operating margins.
Material Changes
The primary material change is the execution of a specific tranche under the amended Securities Purchase Agreements (SPAs) originally dated September 17, 2025, and amended on April 30, 2026. This agreement allows for the issuance of up to $10,000,000 in convertible promissory notes. The June 1, 2026 transaction represents the issuance of $1,500,000 of this authorized amount.
Outlook, Risks, and Management Commentary
Management, represented by CEO Adi Zuloff-Shani, has authorized the issuance of these notes to CLA Investors. The filing incorporates this report by reference into various Registration Statements on Form F-3 and Form S-8. No specific forward-looking guidance, risk factors, or unusual items beyond the standard terms of the convertible note issuance are detailed in this specific text.
Investor Verification Checklist
- Verify the closing date and actual receipt of the $1,350,000 cash proceeds.
- Review the full terms of the convertible promissory notes, including conversion rates, interest rates, and maturity dates, which are not detailed in this summary.
- Confirm the remaining capacity under the $10,000,000 aggregate principal limit established in the April 30, 2026 amendment.
- Check for any subsequent filings that may supersede the registration statements referenced in this Form 6-K.